Gibson Christopher 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Mar 25, 2026
Research Summary
AI-generated summary of this filing
Recursion (RXRX) Director Christopher Gibson Sells 40,000 Shares
What Happened Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), converted derivative holdings into common stock and sold 40,000 shares in an open-market transaction on March 23, 2026. The shares sold were disposed at $3.25 each, generating $130,000 in proceeds. The conversion entries (40,000 shares acquired at $0.00 and a corresponding 40,000-share derivative disposition at $0.00) reflect the conversion of derivative securities into shares (see footnote F1).
Key Details
- Transaction date: March 23, 2026. Sale price: $3.25 per share; total proceeds $130,000.
- Conversions: Two derivative conversion entries (40,000 shares acquired at $0.00; 40,000 shares disposed at $0.00) indicate conversion of derivative holdings to common shares (F1).
- Sale execution: Open-market sale pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025 (F2).
- Shares owned after transaction: Not specified in the provided summary—see the full Form 4 for aggregate holdings and post-transaction totals.
- Other footnotes note ownership through family entities/LLCs (F3–F5) and various option vesting schedules (F6–F10) unrelated to this immediate sale.
- Filing: Report filed March 25, 2026 (two days after the trade date), which appears timely under Form 4 rules.
Context This was a sale (a disposition) rather than a purchase—sales may be routine or for liquidity and, in this case, were carried out under a pre-arranged 10b5-1 plan (F2), which typically schedules trades in advance. The conversion entries are not a cash purchase; they reflect conversion of derivative securities (e.g., Class B to Class A per F1) into tradable shares that were then sold. For full details on holdings and any option vesting referenced in the footnotes, consult the complete Form 4 filing.
Insider Transaction Report
- Conversion
Class A Common Stock
[F1][F2]2026-03-23+40,000→ 946,556 total - Sale
Class A Common Stock
[F2]2026-03-23$3.25/sh−40,000$130,000→ 906,556 total - Conversion
Class B Common Stock
[F1]2026-03-23−40,000→ 4,483,334 totalExercise: $0.00→ Class A Common Stock (40,000 underlying)
- 386,000(indirect: By LLC)
Class B Common Stock
[F1][F3]Exercise: $0.00→ Class A Common Stock (0 underlying) - 388,000(indirect: By LLC)
Class B Common Stock
[F1][F4]Exercise: $0.00→ Class A Common Stock (0 underlying) - 50,000(indirect: By Trust)
Class B Common Stock
[F1][F5]Exercise: $0.00→ Class A Common Stock (0 underlying) - 1,050,567
Stock Option (Right to Buy)
[F6]Exercise: $7.25Exp: 2035-02-03→ Class A Common Stock (0 underlying) - 666,898
Stock Option (Right to Buy)
[F7]Exercise: $10.09Exp: 2034-02-09→ Class A Common Stock (0 underlying) - 813,600
Stock Option (Right to Buy)
[F8]Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying) - 399,002
Stock Option (Right to Buy)
[F9]Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 5,436
Stock Option (Right to Buy)
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 282,500
Stock Option (Right to Buy)
[F10]Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (0 underlying)
Footnotes (10)
- [F1]Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- [F10]The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F2]This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- [F3]The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- [F4]The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- [F5]The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- [F6]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F7]The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F8]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F9]The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.